Sökning: WFRF:(Wigren Edvard) >
Anti-FHL1 autoantib...
Anti-FHL1 autoantibodies in adult patients with myositis: a longitudinal follow-up analysis
-
- Galindo-Feria, Angeles S. (författare)
- Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
-
- Lodin, Karin (författare)
- Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
-
- Horuluoglu, Begum (författare)
- Karolinska Institutet,Karolinska Inst, Sweden
-
visa fler...
-
- Sarrafzadeh-Zargar, Sepehr (författare)
- Karolinska Inst, Sweden
-
- Wigren, Edvard (författare)
- Karolinska Inst, Sweden
-
- Graslund, Susanne (författare)
- Karolinska Inst, Sweden
-
- Danielsson, Olof (författare)
- Linköpings universitet,Avdelningen för cell- och neurobiologi,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping
-
- Wahren-Herlenius, Marie (författare)
- Karolinska Inst, Sweden; Univ Bergen, Norway
-
- Dastmalchi, Maryam (författare)
- Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
-
- Lundberg, Ingrid E. (författare)
- Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2024
- 2024
- Engelska.
-
Ingår i: Rheumatology. - : OXFORD UNIV PRESS. - 1462-0324 .- 1462-0332.
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives: To determine prevalence and clinical associations of anti-Four-and-a-half-LIM-domain 1 (FHL1) autoantibodies in patients with idiopathic inflammatory myopathies (IIM) and to evaluate autoantibody levels over time. Methods: Sera at the time of diagnosis from patients with IIM (n = 449), autoimmune disease controls (DC, n = 130), neuromuscular diseases (NMDs, n = 16) and healthy controls (HC, n = 100) were analysed for anti-FHL1 autoantibodies by enzyme-linked immunosorbent assay (ELISA). Patients with IIM FHL1+ and FHL1- were included in a longitudinal analysis. Serum levels were correlated to disease activity. Results: Autoantibodies to FHL1 were more frequent in patients with IIM (122/449, 27%) compared with DC (autoimmune DC and NMD, 13/146, 9%, P < 0.001) and HC (3/100.3%, P < 0.001). Anti-FHL1 levels were higher in IIM [median (IQR)=0.62 (0.15-1.04)] in comparison with DC [0.22 (0.08-0.58)], HC [0.35 (0.23-0.47)] and NMD [0.48 (0.36-0.80)] P < 0.001. Anti-FHL1+ patients with IIM were younger at the time of diagnosis compared with the anti-FHL1- group (P = 0.05) and were seronegative for other autoantibodies in 25%.<br /> In the first follow-up, anti-FHL1+ sample 20/33 (60%) positive at baseline had turned negative for anti-FHL1 autoantibodies. Anti-FHL1 autoantibodies rarely appeared after initiating treatment. Anti-FHL1 autoantibody levels correlated with CK (r = 0.62, P= 0.01), disease activity measured using the Myositis Disease Activity Assessment Tool (MYOACT) (n = 14, P = 0.004) and inversely with Manual Muscle Test-8 (r = -0.59, P = 0.02) at baseline. Conclusion: Anti-FHL1 autoantibodies were present in 27% of patients with IIM; of these, 25% were negative for other autoantibodies. Other autoimmune diseases had lower frequencies and levels. Anti-FHL1 levels often decreased with immunosuppressive treatment, correlated with disease activity measures at diagnosis and rarely appeared after start of treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Nyckelord
- autoantibody; idiopathic inflammatory myopathy; myositis; FHL1
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas